{"ticker": {"uuid": "83665e9f-5d39-4e90-a8a6-5f602824385c", "symbol": "HUMA", "name": "Humacyte Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know", "summary": "Humacyte, Inc. (HUMA) saw its stock price increase by 2.31% in a recent trading session, outperforming the S&P 500, Dow, and Nasdaq. The company is projected to report a significant increase in EPS and revenue in its upcoming financial release. Despite a recent downward shift in ", "url": "https://sg.finance.yahoo.com/news/humacyte-inc-huma-beats-stock-221502216.html", "source_name": "Market source", "published_at": "2026-07-15T06:12:14", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte appoints two nephrologists as commercial advisors By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR3g4TXdfdGprOER5ajBCdHVTTnlPcEZJMVdwRXJrSUNHWFBKVU5hRWZ4QjFOOG53ZnJOQzUtTlI4TUUxMDROM0Zyb3J4YlNMMVFKZ2VSM2tWZ3dUaENieHQtY0U0cmUwZVNrLXhSM2E2clhvMm15YnltR1lDX25fUGk2eWp4ZDRVNGdwVFU0cTU2b1JxbXQzUERBMWJiczNMWGtLY3JsbnY0NmZFaGhlYXNWNGdUTC1fb24w?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T14:59:49+00:00", "published_display": "14 Jul 2026 14:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte appoints two nephrologists as commercial advisors", "summary": "Humacyte, Inc. (NASDAQ:HUMA) has appointed Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as commercial advisors to assist with the planned commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. This move follows positive results from its", "url": "https://www.investing.com/news/company-news/humacyte-appoints-two-nephrologists-as-commercial-advisors-93CH-4790730", "source_name": "Investing.com", "published_at": "2026-07-14T15:11:15", "published_display": "14 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access", "summary": "Humacyte has announced the appointment of Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to assist with the planned commercialization of their acellular tissue engineered vessel (ATEV) for hemodialysis access. These leading nephrologists will contribute to health", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-planned-commercialization-of-the-atev-in-dialysis-access/2384044/amp", "source_name": "The Manila Times", "published_at": "2026-07-14T12:11:16", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis Access", "summary": "Humacyte (Nasdaq: HUMA) has appointed leading nephrologists Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. These appointments follow positive Phase 3 study ", "url": "https://www.stocktitan.net/news/HUMA/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-gn5sk8yfrjhf.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:11:15", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A HUMACYTE For: 13 July By Investing.com", "summary": "This article provides details about a Form 13D/A filing for HUMACYTE on July 13. It includes the stock symbol HUMA and details a slight price increase of 2.10%. The content is brief, primarily serving as an announcement of the SEC filing.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-humacyte-for-13-july-93CH-2597674", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:28:00", "published_display": "13 Jul 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan", "summary": "Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG plan to reduce their stake in Humacyte, Inc. by selling up to 5,000,000 common shares through a Rule 10b5-1 trading plan. This move is part of FME AG's \"FME Reignite\" strategy, aiming to lower their beneficial ow", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13d-a-humacyte-inc-amended-major-shareholder-report-6a43a38608fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:42:35", "published_display": "13 Jul 2026 21:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "HUMA - Humacyte Inc Options", "summary": "This article provides a detailed financial overview of Humacyte Inc. (HUMA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS growth, insider and institutional ownership, profi", "url": "https://finviz.com/stock?t=HUMA&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_date&e=2026-12-18", "source_name": "Finviz", "published_at": "2026-07-04T15:09:27", "published_display": "04 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 NASDAQ:HUMAW", "summary": "This article provides a brief financial overview for Humacyte, Inc. (NASDAQ: HUMAW), focusing on its enterprise value to revenue forward metric. The content highlights the company's stock market information and indicates a focus on financial data without elaborating on specific f", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:39:34", "published_display": "01 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings", "summary": "This page provides access to Humacyte, Inc.'s SEC filings and other important company documents, including earnings reports, annual and quarterly reports, corporate presentations, and event transcripts. The documents span from 2026 back to 2023, offering detailed insights into th", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMAW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:11:37", "published_display": "01 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why", "summary": "Humacyte Inc.'s stock (HUMA) dropped by 2.32% on the last trading day, underperforming the broader market gains. Over the past month, the stock has fallen 44.9%. Analysts project positive earnings and revenue growth for the upcoming quarter, but the company currently holds a Zack", "url": "https://ca.finance.yahoo.com/news/humacyte-inc-huma-stock-sinks-220002665.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-30T22:00:00", "published_display": "30 Jun 2026 22:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Announces $50 Million Public Offering of Common Stock", "summary": "Humacyte Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company, has announced a $50 million public offering of common stock. Paul Hastings LLP advised Barclays, BTIG, and Titan Partners on the offering, while Covington & Burling LLP advised Humacyte Inc. Further ", "url": "https://globallegalchronicle.com/post-236152/", "source_name": "Global Legal Chronicle", "published_at": "2026-06-30T00:11:13", "published_display": "30 Jun 2026 00:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA)", "summary": "This article provides an overview of Humacyte, Inc. (NASDAQ:HUMA) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics like market capitalization, earnings, revenue, and EBITDA, along with information on future e", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T05:09:57", "published_display": "28 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 NASDAQ:HUMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSVRyYjFmd3dlOEdCQXBMRVZuSjNoTFVzaF9lcm5CZmhxOE1vcXA0WlBUbjNCWDd6ak5Ta0dKRl9kQW0yby1uUnBZSXhmbE9Vb2JicGhMN1F4Wl9vU3hoelhpR0JVT0p1SFVfZ3hkeWQ4cEplVFcwVG9wdThHa0c4UE9odm1WZDdKZ1J3dGZxRVJKejQtcHJ6Zk5qQ3lIdGt5cHRkTzNwMkM1VnBp?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T03:53:16+00:00", "published_display": "28 Jun 2026 03:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Humacyte, Inc. \u2013 NASDAQ:HUMA", "summary": "This page from TradingView provides a financial overview for Humacyte, Inc. (NASDAQ: HUMA), specifically focusing on its price-to-earnings forward metric. The content highlights the company's stock market information and indicates no recent trades, suggesting the market was close", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:24", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data", "summary": "Humacyte's (HUMA) fair value estimate has significantly decreased from US$7.86 to US$2.05 following the V012 data release, reflecting split analyst views. While some analysts are bullish on the acellular vessel opportunity, others have trimmed expectations due to increased cautio", "url": "https://finance.yahoo.com/markets/stocks/articles/humacyte-huma-stock-fair-value-140656502.html", "source_name": "Market source", "published_at": "2026-06-27T10:06:00", "published_display": "27 Jun 2026 10:06", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Humacyte, Inc. \u2013 BOATS:HUMA", "summary": "This article provides financial information for Humacyte, Inc. (HUMA) on the TradingView platform, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's stock symbol on the Blue Ocean Alternative Trade System (BOATS). The brief articl", "url": "https://www.tradingview.com/symbols/BOATS-HUMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:29", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 BOATS:HUMA", "summary": "The article provides the enterprise value to revenue forward for Humacyte, Inc. (HUMA) on the Blue Ocean Alternative Trade System (BOATS:HUMA). It highlights that the market was closed at the time of publication, with no trades reported. The information is presented within the co", "url": "https://www.tradingview.com/symbols/BOATS-HUMA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:20", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPWTkwWlVKb0FDU3phVUZRY2lfS0k0RVNWQXJhRGFJR1lhWTlJUXlkdzNxTjlZRGpKS3hlSFFKbzY4WjFDUDd1RGQ5dGJyU21NS3VoMGNVMlY3dUo5dmJOMGZMY1BLNUdtUmd3emI0dk1YcDJpcTBvUldkMWhGV1A2UG1fSmRuQXBtaXBVWkRuX25vd1hPZGFj?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA)", "summary": "Davidson Kempner-affiliated entities have reported a 4.74% stake in Humacyte (NASDAQ: HUMA) through a Schedule 13G filing. This amounts to 12,787,073 shares, calculated based on 269,638,156 shares outstanding. Anthony A. Yoseloff is identified as responsible for the voting and in", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13g-humacyte-inc-passive-investment-disclosure-5-ed7ad0d0fc30.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:40:15", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Humacyte For: 22 June By Investing.com", "summary": "This article reports on a Form 13G filing for Humacyte (HUMA) on June 22. It is a brief announcement from Investing.com and includes financial data and various market indices, but no specific details about the filing itself. The article also contains a list of popular news and ma", "url": "https://ca.investing.com/news/stock-market-news/form-13g-humacyte-for-22-june-93CH-4702096", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:40:15", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORzdwZnhxdC05MmJ1WFVFdDJrbVVZVTNiVXYxbWp5a01rRU9iWk1RY2lGWnMtcVBlLU9sTlpZaDdBSm1RYUh3T3ZRNVlWSzV0dDhyT2NIVDBMX2NfeWw4Vkd4Tkowb2FybVNnTkFqTFNJU0I3em9pQkQxTEdCYms0OEJVdlhEaU83NEFFQUZVbnczMHdYSVFxY2kwb2hBNUVGM3oyYi1R?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) dips more than broader market: What you should know", "summary": "This article from MSN discusses that Humacyte, Inc. (HUMA) experienced a stock dip that was more significant than the broader market's decline. It suggests investors might want to investigate the reasons behind this underperformance.", "url": "https://www.msn.com/en-us/money/topstocks/humacyte-inc-huma-dips-more-than-broader-market-what-you-should-know/ar-AA25OBfD", "source_name": "MSN", "published_at": "2026-06-18T17:39:51", "published_display": "18 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Institutional Confidence", "summary": "Humacyte Inc (HUMA) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 29.83% quarter-over-quarter to 32.47%. Fresenius SE & Co KGaA is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:36", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Humacyte Inc (HUMA) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $3.50 for HUMA, with individual targets ranging from $3.00 to $25.00. The company's expected revenue for the next quarter is $1.12 million, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:36", "published_display": "18 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Humacyte Inc's (HUMA) dividend and stock split history.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:33", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Humacyte Inc (HUMA), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant data for several fiscal quarters of FY2025 and FY2022 has not yet been disclosed by the company. The only specif", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:32", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary", "summary": "Humacyte (HUMA) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting the commercial progress of its vascular product, which has seen improved adoption after a price adjustment and increased focus on education. The company detailed positive clinical tri", "url": "https://quartr.com/events/humacyte-inc-huma-barclays-28th-annual-global-healthcare-conference_oqtGGcDK", "source_name": "Quartr", "published_at": "2026-06-16T08:11:09", "published_display": "16 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/humacyte-inc-huma-upgraded-buy-160003155.html", "source_name": "Zacks", "published_at": "2026-06-15T16:00:03+00:00", "published_display": "15 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results", "summary": "Humacyte (NASDAQ:HUMA) announced positive Phase 3 V012 trial results for its bioengineered blood vessel (ATEV), demonstrating superiority over traditional AV fistulas for women on dialysis. The ATEV showed a significant increase in catheter-free days and a lower infection rate. H", "url": "https://grafa.com/en/news/united-states/humacyte-huma-v012-phase-3-results", "source_name": "grafa.com", "published_at": "2026-06-15T14:38:57", "published_display": "15 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure", "summary": "Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG disclosed an updated beneficial ownership of 18,312,735 shares, representing 6.8% of Humacyte's outstanding common stock. This percentage decreased from 8.4% not due to share disposition by Fresenius, but solely ", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13d-a-humacyte-inc-amended-major-shareholder-report-27d5c0daf9f4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T13:38:56", "published_display": "15 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/humacytes-bioengineered-blood-vessel-outperforms-120000200.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:00:00+00:00", "published_display": "15 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioengineered blood vessel helps women on dialysis avoid catheters longer", "summary": "Humacyte's bioengineered blood vessel (ATEV) significantly outperformed the standard AV fistula in a Phase 3 study for women on dialysis, leading to more catheter-free days and fewer infections. The positive results support Humacyte's plan to file a supplemental Biologics License", "url": "https://www.stocktitan.net/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-23ehzffodu1u.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:38:57", "published_display": "15 Jun 2026 11:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQLTMtQzF0Skt1Z2hTaG0tdFVpMHdSMjVXZVk5WTFGN0QzTEtvMHdiZ0dUUmx1aWZZYVJabGpsSkp5cFpQdHdoSm03cldvUm9nbFZTMi1HY3ZGUTdEMDlTWFZGdlFEckZMNWtJYzB1SThrWUtlWVNvSHRISE5HVldCeHNoTDZtbjd2SXpXZ2VuNUVySFNUNElveXl0VVlKOU5yVllMaA?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Humacyte plans stock sale to fund Symvess dialysis push", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUGVpeVJDVkNWTHNKOHNuOUJ1bkZLeUNBLTF1blpqYjVsbzNLelJISVNqNzR5TUdsZUdXMkFpQVBzUkhMRTE4UDVmaTctOTRlQXBlUXVqbkd5Y0t4RXB1QjNoMTJ3V3phNi1DUGRVUFlfaFVXQ2ZGaC1UdWVzVW5uTjJYYUVwdVBPaGNKQkw5NEpNZG5wRHZuM0kxRUFTZTBKUHZWYjFxNm5jT05aUTdOUXhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte launches public offering of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOams1ZkllQmdNUGFyX04zTFFLbTFzTUtrYzB2cC1zMy1MckYzTk91UUFrSUlXcHEzbHhQcFhRMDROY2QtRW9PakV1LVphb0JYQUVnclpFS3JtckVhSVc2T1VrOTBveXA4SUQ5MVlzZ3hzQV9tMWJ4M3R0TXZHWmwxR3I0OUpoa2twZTFNSUFFZ3Z1LVZ6UmhycVYtdmZYYkdPa0p2cmZQc0xhZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTGZVUkFKelk1b2cwVVRpTHBjQ2tMV1l5V1lOTjdHNzFOdlJqemtHSmN4TjgxNS1CSDJJLWlqZElEdVpBSzFnMmZ4OGR0b1dMMEFxM21oY1dtLWtNU1VSSG9VcTdXMFl3cllvLTdYOGJjcENSNTFMUE56NlJFSEpOR3luSnpOZHhwN0VfRmEtdTFZYUhSREllcTBybFZuWkxscDdlM0dJNVdtekIxMmhYMkIwekM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark raises Humacyte stock price target on dialysis launch hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRm5TS1Y0UWdYS0xDZjZ4eWxDdGE1WEJzLXo5TUo0MWhnZXhacnh4aVdEQWVuQmR1YWtHc01kcWVVTTAteWRzTjJGLXp2RjdNMVgwb3kza3JyQTFaZjVYRks1S1lnTUd1c3RraTlOS0tGRnc2RVA2ZkFUdzRNYlNrbktYR091RGFWTzFwM3Jtb3hCaVJFaW9xNVpoaUwyQ3FqNjZaaEtDQ3JTb0ZfRy04dmNtTXFJSHBLOGhiYjdMenNnUGZWUWhwYw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Is Up 23.8% After New ATEV Self\u2011Repair Data And Phase 3 Timeline Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VA hospitals to get easier access to Humacyte Symvess product", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQU0lTc3RmTkZQTW1hb3cwaHVCV1Z5NGN6NTNMeEpwdE0xd2FxTHNKNU5EaFBOWkZiMEx5NG5RVXpQaE5VdkxKcmZDczN3ZzZvVVpZc0xEMmxwNVhHTDEzWHFDcFhETzNnOWtablVZeWtySnc1MXdoQUtRcWR6dE5yM1JnV3VlMk1PV2tBQ0lWR3VvNWZMYnFqUG1fclRyUzBMa1IzUXE3NVBjaW0zcmNCdjZtcUJ1LTB6eEcwY3VWQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Humacyte (NASDAQ: HUMA) faces 180-day window to fix Nasdaq $1 bid-price deficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQc19yclJaWEROVHpRTTFiWmtieTZGX3I1NkJqMHNDVXBhU19lQnk0WHhjbnJKTTBXR2NFR29WNjg1VXFIWDZXNzE3OGxKNGRTYW85dGlfOHhnV2NMVVdUMXVlOEdnZU5tc3dBazJIbGVMS2xnbjVhTEhVcC1HVmMtWk81MC1WNHdkMlJ2T2NVaW9ZcWtXeVd5ZnFjaHdRQlNobDhJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQYWNXMm8zeU1uc25jUlpnSW9QREVjRUFqRkp3Y0QwQ3E2TzZNdGFrdGVwVTU1WE8zLUpHVUdCWmVyWVRKclNidlhiSVVaWDNWcUNfSTZ3eHJpMlJBbFJXdmRuQTlZODBEa3J4emJlMFVVUU5hbFlpWWRjdjNGREdXOFJkemNTRWd0N3oxamJCbFVoUk5WSkcxdUI2ZlJGQXVjblNCTXZuZkNrdWpGZTFKbEVFYWJWUGVjdTdPVVFsRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Humacyte regains ex-U.S. rights to Symvess from Fresenius", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOGRCNVQ0OUt5OHFYVGhaYTYyai1VZnlMSHY5bGFRTE5JSUFPbnRMTlItWjdfRDVWcDdxM1JpNWI1Q2RNUGR5ZWpsMTlLXzJrelRWa3VuRkx2Um9MX3ZxclRPalV4OHZYdzJuYWU5NHZtR1BNSG9FQ2EybEd3UkgtRUxiMHVkQWlrdVpYNDY1T09pRkFvc1paZUQ3Ty0tRVI3TDRCRWhuQVozOC1FandyXw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOSWVMakZ5NW5YczdFOEc2YlBsM0s2YXZyU2NuRjdfTWZMVG5SZmxsR3BBVzNUWkdvd1RNeDRRV2VETjFIVEQ2azhKSVNGOGIyQVBwSDlBcFBCc0NzTGIyNVoxaGo5MXhYN2pLVkhJQVlVcUFaTE1UVzVCSU1JN28wNmlqcC0zR1RaZER1TEZNdkN5ZTJSUm1fdDF5YWgzdw?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNd3Zoc2lvb1VyNnE5YjZKQWdfcmRvdnQ1dFk1RmJ1Mk5iZkppR2dOdmJhOUJKdEZLZEhfa2d2czE1SldlN21icnlZUFZQWHQ5djJNckVhRS1GQjdScnpNM05JOWRSa2loN1ItcXNyYU1Xc2FVYWcxSlk5aklRbjNVTWNrekJ2QVctUGRnbGJjZmFUalNWNVB3OQ?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (Nasdaq: HUMA) prices $20M registered direct stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSlAycW9TTGgxUkJEZ0txZFR6UFYzUk02bFhCcktrYXdxMFBHREFJb1VmSF9pRWhIWmpRV0dLME0tOWhOd1d2N24wMzA2R2ZSMlhLLW9tSmxMUTlZU2RvZ2t6WWZnWUlqSllUdmlwTnZwYm94cHBUS1VxTE5yZ19iLVlfQy11NFdJYjZTR2tpOU9KVktKaVJQQkc4eFlkVlBId2lJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWGI1MUpqbmhmMHNsX2p6d01YVy1MZEVJNEw1NzVCUmNfdHY0d0RjZ3dSRGhvSUFJNEYwQnZERmxGc1FxMjktWVhCOXlhUnZnNlNleGREc21wT0RSSjNUR1ZuWk5JUHUwTnU5RXhicWRWX0pNU2FSZ3IzMk9iMHlFQVl1TzRSOUtIb05HMURUNUZ5d0p0ZmpjTFhnY3lzZFVRTWFIRkVYZXJIM2M?oc=5", "source_name": "Newswire.com", "published_at": "2025-10-14T07:00:00+00:00", "published_display": "14 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcmlWVjRLNXJfSElpSU04X0d4U3V3aTdsVWZ2TGtoZzF1aUFHTFNzQ2puSTV2WFF1OUdNdjNUUmdMdnBVcXpYSDdVcm9icVdDX1hHQ3BQTWJlcFNqTElpM2lGamJaVHpRbVhFQ1NJb3FCNnJxd1g1aGp1bm5zYkFJTjJOY0NIa3JORFVqRzlxNlZRbFlrcWNtQ05UaERzOWw2b0dIX1Nhd0hlVFpkYmloMElIVVhSc1Z3QlFXNnpyelhwSlJ6SmRQQTRMTU_SAdIBQVVfeXFMT1FOZXdKS3NLLWVvVVlSSWFyRWl6THVLNGFnSVlLanZYLUl1VThmSG5JU1FYU0M1MHdvby1JQWRiT2ZFWnE1XzhFelYtZjVnMjJIck9zSG9IckY0b1NBUGhaOVp3YktINDdPaTBpR3BlMldBWEtTSUczMktBa2lOMmZ6ekdfZnVBNURHUlhYbEc0blNndmFLZE9tbkNjVzVXLVpVUElKNzFkSWc5bUNURGI3cEliT0J0bDhGcWlZUHZ5LWl3Y3FLa0NTZnI1RXpPamNR?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know", "summary": "Humacyte, Inc. (HUMA) saw its stock price increase by 2.31% in a recent trading session, outperforming the S&P 500, Dow, and Nasdaq. The company is projected to report a significant increase in EPS and revenue in its upcoming financial release. Despite a recent downward shift in ", "url": "https://sg.finance.yahoo.com/news/humacyte-inc-huma-beats-stock-221502216.html", "source_name": "Market source", "published_at": "2026-07-15T06:12:14", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte appoints two nephrologists as commercial advisors By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR3g4TXdfdGprOER5ajBCdHVTTnlPcEZJMVdwRXJrSUNHWFBKVU5hRWZ4QjFOOG53ZnJOQzUtTlI4TUUxMDROM0Zyb3J4YlNMMVFKZ2VSM2tWZ3dUaENieHQtY0U0cmUwZVNrLXhSM2E2clhvMm15YnltR1lDX25fUGk2eWp4ZDRVNGdwVFU0cTU2b1JxbXQzUERBMWJiczNMWGtLY3JsbnY0NmZFaGhlYXNWNGdUTC1fb24w?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T14:59:49+00:00", "published_display": "14 Jul 2026 14:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte appoints two nephrologists as commercial advisors", "summary": "Humacyte, Inc. (NASDAQ:HUMA) has appointed Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as commercial advisors to assist with the planned commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. This move follows positive results from its", "url": "https://www.investing.com/news/company-news/humacyte-appoints-two-nephrologists-as-commercial-advisors-93CH-4790730", "source_name": "Investing.com", "published_at": "2026-07-14T15:11:15", "published_display": "14 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access", "summary": "Humacyte has announced the appointment of Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to assist with the planned commercialization of their acellular tissue engineered vessel (ATEV) for hemodialysis access. These leading nephrologists will contribute to health", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-planned-commercialization-of-the-atev-in-dialysis-access/2384044/amp", "source_name": "The Manila Times", "published_at": "2026-07-14T12:11:16", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis Access", "summary": "Humacyte (Nasdaq: HUMA) has appointed leading nephrologists Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. These appointments follow positive Phase 3 study ", "url": "https://www.stocktitan.net/news/HUMA/humacyte-appoints-key-nephrologists-as-advisors-to-prepare-for-gn5sk8yfrjhf.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:11:15", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A HUMACYTE For: 13 July By Investing.com", "summary": "This article provides details about a Form 13D/A filing for HUMACYTE on July 13. It includes the stock symbol HUMA and details a slight price increase of 2.10%. The content is brief, primarily serving as an announcement of the SEC filing.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-humacyte-for-13-july-93CH-2597674", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:28:00", "published_display": "13 Jul 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan", "summary": "Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG plan to reduce their stake in Humacyte, Inc. by selling up to 5,000,000 common shares through a Rule 10b5-1 trading plan. This move is part of FME AG's \"FME Reignite\" strategy, aiming to lower their beneficial ow", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13d-a-humacyte-inc-amended-major-shareholder-report-6a43a38608fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:42:35", "published_display": "13 Jul 2026 21:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUMA - Humacyte Inc Options", "summary": "This article provides a detailed financial overview of Humacyte Inc. (HUMA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS growth, insider and institutional ownership, profi", "url": "https://finviz.com/stock?t=HUMA&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_date&e=2026-12-18", "source_name": "Finviz", "published_at": "2026-07-04T15:09:27", "published_display": "04 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 NASDAQ:HUMAW", "summary": "This article provides a brief financial overview for Humacyte, Inc. (NASDAQ: HUMAW), focusing on its enterprise value to revenue forward metric. The content highlights the company's stock market information and indicates a focus on financial data without elaborating on specific f", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:39:34", "published_display": "01 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings", "summary": "This page provides access to Humacyte, Inc.'s SEC filings and other important company documents, including earnings reports, annual and quarterly reports, corporate presentations, and event transcripts. The documents span from 2026 back to 2023, offering detailed insights into th", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMAW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:11:37", "published_display": "01 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why", "summary": "Humacyte Inc.'s stock (HUMA) dropped by 2.32% on the last trading day, underperforming the broader market gains. Over the past month, the stock has fallen 44.9%. Analysts project positive earnings and revenue growth for the upcoming quarter, but the company currently holds a Zack", "url": "https://ca.finance.yahoo.com/news/humacyte-inc-huma-stock-sinks-220002665.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-30T22:00:00", "published_display": "30 Jun 2026 22:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Announces $50 Million Public Offering of Common Stock", "summary": "Humacyte Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company, has announced a $50 million public offering of common stock. Paul Hastings LLP advised Barclays, BTIG, and Titan Partners on the offering, while Covington & Burling LLP advised Humacyte Inc. Further ", "url": "https://globallegalchronicle.com/post-236152/", "source_name": "Global Legal Chronicle", "published_at": "2026-06-30T00:11:13", "published_display": "30 Jun 2026 00:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA)", "summary": "This article provides an overview of Humacyte, Inc. (NASDAQ:HUMA) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics like market capitalization, earnings, revenue, and EBITDA, along with information on future e", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T05:09:57", "published_display": "28 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 NASDAQ:HUMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSVRyYjFmd3dlOEdCQXBMRVZuSjNoTFVzaF9lcm5CZmhxOE1vcXA0WlBUbjNCWDd6ak5Ta0dKRl9kQW0yby1uUnBZSXhmbE9Vb2JicGhMN1F4Wl9vU3hoelhpR0JVT0p1SFVfZ3hkeWQ4cEplVFcwVG9wdThHa0c4UE9odm1WZDdKZ1J3dGZxRVJKejQtcHJ6Zk5qQ3lIdGt5cHRkTzNwMkM1VnBp?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T03:53:16+00:00", "published_display": "28 Jun 2026 03:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Humacyte, Inc. \u2013 NASDAQ:HUMA", "summary": "This page from TradingView provides a financial overview for Humacyte, Inc. (NASDAQ: HUMA), specifically focusing on its price-to-earnings forward metric. The content highlights the company's stock market information and indicates no recent trades, suggesting the market was close", "url": "https://www.tradingview.com/symbols/NASDAQ-HUMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:24", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data", "summary": "Humacyte's (HUMA) fair value estimate has significantly decreased from US$7.86 to US$2.05 following the V012 data release, reflecting split analyst views. While some analysts are bullish on the acellular vessel opportunity, others have trimmed expectations due to increased cautio", "url": "https://finance.yahoo.com/markets/stocks/articles/humacyte-huma-stock-fair-value-140656502.html", "source_name": "Market source", "published_at": "2026-06-27T10:06:00", "published_display": "27 Jun 2026 10:06", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Humacyte, Inc. \u2013 BOATS:HUMA", "summary": "This article provides financial information for Humacyte, Inc. (HUMA) on the TradingView platform, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's stock symbol on the Blue Ocean Alternative Trade System (BOATS). The brief articl", "url": "https://www.tradingview.com/symbols/BOATS-HUMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:29", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Humacyte, Inc. \u2013 BOATS:HUMA", "summary": "The article provides the enterprise value to revenue forward for Humacyte, Inc. (HUMA) on the Blue Ocean Alternative Trade System (BOATS:HUMA). It highlights that the market was closed at the time of publication, with no trades reported. The information is presented within the co", "url": "https://www.tradingview.com/symbols/BOATS-HUMA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:20", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPWTkwWlVKb0FDU3phVUZRY2lfS0k0RVNWQXJhRGFJR1lhWTlJUXlkdzNxTjlZRGpKS3hlSFFKbzY4WjFDUDd1RGQ5dGJyU21NS3VoMGNVMlY3dUo5dmJOMGZMY1BLNUdtUmd3emI0dk1YcDJpcTBvUldkMWhGV1A2UG1fSmRuQXBtaXBVWkRuX25vd1hPZGFj?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA)", "summary": "Davidson Kempner-affiliated entities have reported a 4.74% stake in Humacyte (NASDAQ: HUMA) through a Schedule 13G filing. This amounts to 12,787,073 shares, calculated based on 269,638,156 shares outstanding. Anthony A. Yoseloff is identified as responsible for the voting and in", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13g-humacyte-inc-passive-investment-disclosure-5-ed7ad0d0fc30.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:40:15", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Humacyte For: 22 June By Investing.com", "summary": "This article reports on a Form 13G filing for Humacyte (HUMA) on June 22. It is a brief announcement from Investing.com and includes financial data and various market indices, but no specific details about the filing itself. The article also contains a list of popular news and ma", "url": "https://ca.investing.com/news/stock-market-news/form-13g-humacyte-for-22-june-93CH-4702096", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:40:15", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORzdwZnhxdC05MmJ1WFVFdDJrbVVZVTNiVXYxbWp5a01rRU9iWk1RY2lGWnMtcVBlLU9sTlpZaDdBSm1RYUh3T3ZRNVlWSzV0dDhyT2NIVDBMX2NfeWw4Vkd4Tkowb2FybVNnTkFqTFNJU0I3em9pQkQxTEdCYms0OEJVdlhEaU83NEFFQUZVbnczMHdYSVFxY2kwb2hBNUVGM3oyYi1R?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) dips more than broader market: What you should know", "summary": "This article from MSN discusses that Humacyte, Inc. (HUMA) experienced a stock dip that was more significant than the broader market's decline. It suggests investors might want to investigate the reasons behind this underperformance.", "url": "https://www.msn.com/en-us/money/topstocks/humacyte-inc-huma-dips-more-than-broader-market-what-you-should-know/ar-AA25OBfD", "source_name": "MSN", "published_at": "2026-06-18T17:39:51", "published_display": "18 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Institutional Confidence", "summary": "Humacyte Inc (HUMA) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 29.83% quarter-over-quarter to 32.47%. Fresenius SE & Co KGaA is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:36", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Humacyte Inc (HUMA) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $3.50 for HUMA, with individual targets ranging from $3.00 to $25.00. The company's expected revenue for the next quarter is $1.12 million, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:36", "published_display": "18 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Humacyte Inc's (HUMA) dividend and stock split history.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:33", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Humacyte Inc (HUMA), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant data for several fiscal quarters of FY2025 and FY2022 has not yet been disclosed by the company. The only specif", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-huma/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:32", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary", "summary": "Humacyte (HUMA) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting the commercial progress of its vascular product, which has seen improved adoption after a price adjustment and increased focus on education. The company detailed positive clinical tri", "url": "https://quartr.com/events/humacyte-inc-huma-barclays-28th-annual-global-healthcare-conference_oqtGGcDK", "source_name": "Quartr", "published_at": "2026-06-16T08:11:09", "published_display": "16 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/humacyte-inc-huma-upgraded-buy-160003155.html", "source_name": "Zacks", "published_at": "2026-06-15T16:00:03+00:00", "published_display": "15 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results", "summary": "Humacyte (NASDAQ:HUMA) announced positive Phase 3 V012 trial results for its bioengineered blood vessel (ATEV), demonstrating superiority over traditional AV fistulas for women on dialysis. The ATEV showed a significant increase in catheter-free days and a lower infection rate. H", "url": "https://grafa.com/en/news/united-states/humacyte-huma-v012-phase-3-results", "source_name": "grafa.com", "published_at": "2026-06-15T14:38:57", "published_display": "15 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure", "summary": "Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG disclosed an updated beneficial ownership of 18,312,735 shares, representing 6.8% of Humacyte's outstanding common stock. This percentage decreased from 8.4% not due to share disposition by Fresenius, but solely ", "url": "https://www.stocktitan.net/sec-filings/HUMA/schedule-13d-a-humacyte-inc-amended-major-shareholder-report-27d5c0daf9f4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T13:38:56", "published_display": "15 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/humacytes-bioengineered-blood-vessel-outperforms-120000200.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:00:00+00:00", "published_display": "15 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioengineered blood vessel helps women on dialysis avoid catheters longer", "summary": "Humacyte's bioengineered blood vessel (ATEV) significantly outperformed the standard AV fistula in a Phase 3 study for women on dialysis, leading to more catheter-free days and fewer infections. The positive results support Humacyte's plan to file a supplemental Biologics License", "url": "https://www.stocktitan.net/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-23ehzffodu1u.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:38:57", "published_display": "15 Jun 2026 11:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQLTMtQzF0Skt1Z2hTaG0tdFVpMHdSMjVXZVk5WTFGN0QzTEtvMHdiZ0dUUmx1aWZZYVJabGpsSkp5cFpQdHdoSm03cldvUm9nbFZTMi1HY3ZGUTdEMDlTWFZGdlFEckZMNWtJYzB1SThrWUtlWVNvSHRISE5HVldCeHNoTDZtbjd2SXpXZ2VuNUVySFNUNElveXl0VVlKOU5yVllMaA?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Humacyte plans stock sale to fund Symvess dialysis push", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUGVpeVJDVkNWTHNKOHNuOUJ1bkZLeUNBLTF1blpqYjVsbzNLelJISVNqNzR5TUdsZUdXMkFpQVBzUkhMRTE4UDVmaTctOTRlQXBlUXVqbkd5Y0t4RXB1QjNoMTJ3V3phNi1DUGRVUFlfaFVXQ2ZGaC1UdWVzVW5uTjJYYUVwdVBPaGNKQkw5NEpNZG5wRHZuM0kxRUFTZTBKUHZWYjFxNm5jT05aUTdOUXhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte launches public offering of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOams1ZkllQmdNUGFyX04zTFFLbTFzTUtrYzB2cC1zMy1MckYzTk91UUFrSUlXcHEzbHhQcFhRMDROY2QtRW9PakV1LVphb0JYQUVnclpFS3JtckVhSVc2T1VrOTBveXA4SUQ5MVlzZ3hzQV9tMWJ4M3R0TXZHWmwxR3I0OUpoa2twZTFNSUFFZ3Z1LVZ6UmhycVYtdmZYYkdPa0p2cmZQc0xhZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTGZVUkFKelk1b2cwVVRpTHBjQ2tMV1l5V1lOTjdHNzFOdlJqemtHSmN4TjgxNS1CSDJJLWlqZElEdVpBSzFnMmZ4OGR0b1dMMEFxM21oY1dtLWtNU1VSSG9VcTdXMFl3cllvLTdYOGJjcENSNTFMUE56NlJFSEpOR3luSnpOZHhwN0VfRmEtdTFZYUhSREllcTBybFZuWkxscDdlM0dJNVdtekIxMmhYMkIwekM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark raises Humacyte stock price target on dialysis launch hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRm5TS1Y0UWdYS0xDZjZ4eWxDdGE1WEJzLXo5TUo0MWhnZXhacnh4aVdEQWVuQmR1YWtHc01kcWVVTTAteWRzTjJGLXp2RjdNMVgwb3kza3JyQTFaZjVYRks1S1lnTUd1c3RraTlOS0tGRnc2RVA2ZkFUdzRNYlNrbktYR091RGFWTzFwM3Jtb3hCaVJFaW9xNVpoaUwyQ3FqNjZaaEtDQ3JTb0ZfRy04dmNtTXFJSHBLOGhiYjdMenNnUGZWUWhwYw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Is Up 23.8% After New ATEV Self\u2011Repair Data And Phase 3 Timeline Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VA hospitals to get easier access to Humacyte Symvess product", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQU0lTc3RmTkZQTW1hb3cwaHVCV1Z5NGN6NTNMeEpwdE0xd2FxTHNKNU5EaFBOWkZiMEx5NG5RVXpQaE5VdkxKcmZDczN3ZzZvVVpZc0xEMmxwNVhHTDEzWHFDcFhETzNnOWtablVZeWtySnc1MXdoQUtRcWR6dE5yM1JnV3VlMk1PV2tBQ0lWR3VvNWZMYnFqUG1fclRyUzBMa1IzUXE3NVBjaW0zcmNCdjZtcUJ1LTB6eEcwY3VWQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (NASDAQ: HUMA) faces 180-day window to fix Nasdaq $1 bid-price deficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQc19yclJaWEROVHpRTTFiWmtieTZGX3I1NkJqMHNDVXBhU19lQnk0WHhjbnJKTTBXR2NFR29WNjg1VXFIWDZXNzE3OGxKNGRTYW85dGlfOHhnV2NMVVdUMXVlOEdnZU5tc3dBazJIbGVMS2xnbjVhTEhVcC1HVmMtWk81MC1WNHdkMlJ2T2NVaW9ZcWtXeVd5ZnFjaHdRQlNobDhJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQYWNXMm8zeU1uc25jUlpnSW9QREVjRUFqRkp3Y0QwQ3E2TzZNdGFrdGVwVTU1WE8zLUpHVUdCWmVyWVRKclNidlhiSVVaWDNWcUNfSTZ3eHJpMlJBbFJXdmRuQTlZODBEa3J4emJlMFVVUU5hbFlpWWRjdjNGREdXOFJkemNTRWd0N3oxamJCbFVoUk5WSkcxdUI2ZlJGQXVjblNCTXZuZkNrdWpGZTFKbEVFYWJWUGVjdTdPVVFsRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte regains ex-U.S. rights to Symvess from Fresenius", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOGRCNVQ0OUt5OHFYVGhaYTYyai1VZnlMSHY5bGFRTE5JSUFPbnRMTlItWjdfRDVWcDdxM1JpNWI1Q2RNUGR5ZWpsMTlLXzJrelRWa3VuRkx2Um9MX3ZxclRPalV4OHZYdzJuYWU5NHZtR1BNSG9FQ2EybEd3UkgtRUxiMHVkQWlrdVpYNDY1T09pRkFvc1paZUQ3Ty0tRVI3TDRCRWhuQVozOC1FandyXw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOSWVMakZ5NW5YczdFOEc2YlBsM0s2YXZyU2NuRjdfTWZMVG5SZmxsR3BBVzNUWkdvd1RNeDRRV2VETjFIVEQ2azhKSVNGOGIyQVBwSDlBcFBCc0NzTGIyNVoxaGo5MXhYN2pLVkhJQVlVcUFaTE1UVzVCSU1JN28wNmlqcC0zR1RaZER1TEZNdkN5ZTJSUm1fdDF5YWgzdw?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNd3Zoc2lvb1VyNnE5YjZKQWdfcmRvdnQ1dFk1RmJ1Mk5iZkppR2dOdmJhOUJKdEZLZEhfa2d2czE1SldlN21icnlZUFZQWHQ5djJNckVhRS1GQjdScnpNM05JOWRSa2loN1ItcXNyYU1Xc2FVYWcxSlk5aklRbjNVTWNrekJ2QVctUGRnbGJjZmFUalNWNVB3OQ?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Humacyte (Nasdaq: HUMA) prices $20M registered direct stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSlAycW9TTGgxUkJEZ0txZFR6UFYzUk02bFhCcktrYXdxMFBHREFJb1VmSF9pRWhIWmpRV0dLME0tOWhOd1d2N24wMzA2R2ZSMlhLLW9tSmxMUTlZU2RvZ2t6WWZnWUlqSllUdmlwTnZwYm94cHBUS1VxTE5yZ19iLVlfQy11NFdJYjZTR2tpOU9KVktKaVJQQkc4eFlkVlBId2lJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWGI1MUpqbmhmMHNsX2p6d01YVy1MZEVJNEw1NzVCUmNfdHY0d0RjZ3dSRGhvSUFJNEYwQnZERmxGc1FxMjktWVhCOXlhUnZnNlNleGREc21wT0RSSjNUR1ZuWk5JUHUwTnU5RXhicWRWX0pNU2FSZ3IzMk9iMHlFQVl1TzRSOUtIb05HMURUNUZ5d0p0ZmpjTFhnY3lzZFVRTWFIRkVYZXJIM2M?oc=5", "source_name": "Newswire.com", "published_at": "2025-10-14T07:00:00+00:00", "published_display": "14 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcmlWVjRLNXJfSElpSU04X0d4U3V3aTdsVWZ2TGtoZzF1aUFHTFNzQ2puSTV2WFF1OUdNdjNUUmdMdnBVcXpYSDdVcm9icVdDX1hHQ3BQTWJlcFNqTElpM2lGamJaVHpRbVhFQ1NJb3FCNnJxd1g1aGp1bm5zYkFJTjJOY0NIa3JORFVqRzlxNlZRbFlrcWNtQ05UaERzOWw2b0dIX1Nhd0hlVFpkYmloMElIVVhSc1Z3QlFXNnpyelhwSlJ6SmRQQTRMTU_SAdIBQVVfeXFMT1FOZXdKS3NLLWVvVVlSSWFyRWl6THVLNGFnSVlLanZYLUl1VThmSG5JU1FYU0M1MHdvby1JQWRiT2ZFWnE1XzhFelYtZjVnMjJIck9zSG9IckY0b1NBUGhaOVp3YktINDdPaTBpR3BlMldBWEtTSUczMktBa2lOMmZ6ekdfZnVBNURHUlhYbEc0blNndmFLZE9tbkNjVzVXLVpVUElKNzFkSWc5bUNURGI3cEliT0J0bDhGcWlZUHZ5LWl3Y3FLa0NTZnI1RXpPamNR?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 61, "sentiment_summary": {"positive": 13, "negative": 9, "neutral": 39, "score": 53, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.85, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 12.65, "count": 25}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.0, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 0.69, "latest_week": "2026-07-10", "one_week_move": -2.3, "four_week_move": -34.2, "twelve_week_move": -2.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.596325, "market_dynamics_buy_signal": false, "relative_strength": -54.16159, "fair_value_gap": -77.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.6146, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, -34.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 7}, {"label": "Investing.com", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "The Manila Times", "count": 2}, {"label": "Investing.com South Africa", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 25}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.3% over one week, -34.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know"}], "updated_at": "2026-07-16T12:57:21.097436+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}